Table 1.
Patient disposition and baseline characteristics
| Study population | |
|---|---|
| Generic entry time | 11/01/2008 |
| No. of patients | 245 |
| No. of censored patients, n (%)a | 140 (57.2) |
| Discontinued treatment (≥1.5 years), n (%) | 0 (0) |
| Did not switch back, n (%) | 140 (57.2) |
| Switched back, n (%) | 105 (42.8) |
| Mean age in years, y (SD) | 42.9 (13.8) |
| Female, n (%) | 131 (53.4) |
| Mean seizure frequency, per month (SD) | 5.952 (58.57) |
| Mean seizure frequency on brand LEV, per month (SD) | 2.473 (8.743) |
| Idiopathic epilepsy, n (%) | 6 (2.4) |
| Symptomatic epilepsy, n (%) | 109 (44.5) |
| Cryptogenic epilepsy, n (%) | 130 (53.1) |
| Polytherapy, n (%) | 158 (64.5) |
| Experienced increased adverse effects on generic LEV, n (%) | 8 (3.3) |
| Experienced increased seizures on generic LEV (rel to brand), n (%) | 48 (19.6) |
| Experienced decreased seizures on generic LEV (rel to brand), n (%) | 4 (1.6) |
a
Defined as discontinued treatment (≥1.5 years) or May 3, 2010, whichever ends first.